Almorexant

DB06673InvestigationalSmall molecule

Investigated for use/treatment in sleep disorders and insomnia.

Chemical structure of Almorexant
Primary indication
Investigated for use/treatment in sleep disorders and insomnia.Curator reviewed
Formula / weight
C29H31F3N2O3 · 512.573 g/mol (avg)
Code names
ACT-078573

Resolves to

Compound
UNII9KCW39P2EICAS871224-64-5ChEMBLCHEMBL455136
Structure
InChIKeyDKMACHNQISHMDN-RPLLCQBOSA-NSMILESCNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Targets
O43613HCRTR1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Almorexant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In